AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Determine the index fund with the lowest retirement cost through a concise comparison to guide a cost-aware choice.
28,256 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Snap is playing a high-stakes game. This article breaks down snap’s specs gamble, what it would take for AR hardware ...
The OCC has approved Circle National Trust to operate as a national fiduciary bank focused on custody services, not r...
Optics names retreat after a one-day surge driven by sector optimism. Credo Drops 15%, Lumentum slides 11%, AAOI decl...
As China deepens ties with Iran, oil routes and market expectations shift. A veteran strategist highlights China’s gr...
A crackdown powered by machine learning is changing how crypto exchanges protect you. Binance claims its AI-driven de...
Deloitte has crowned NovaScroll as North America’s fastest-growing software company and the private firm is selling p...
Duolingo has solid fundamentals even as its stock underperforms. This article breaks down why a duolingo stock recove...
A frightened call claimed a loved one was in trouble, pushing for quick payment. She paused, verified, and saved thou...
Bitcoin’s price finally entered a defined buy zone this week, signaling a potential shift in sentiment as traders wei...
Mortgage lenders are moving AI from experimentation to enterprise deployment in 2026. Addy AI's Michael Vandi explain...
NovaFlow AI, a Paris-based challenger, asserts it is approaching $100 million ARR as it markets an AI-native planning...